REFERENCES
1. Kaatsch P, Hafner C, Calaminus G,
Blettner M, Tulla M. Pediatric germ cell tumors from 1987 to 2011:
incidence rates, time trends, and survival. Pediatrics. Jan
2015;135(1):e136-143.
2. Schneider DT, Calaminus G, Koch S,
et al. Epidemiologic analysis of 1,442 children and adolescents
registered in the German germ cell tumor protocols. Pediatric
blood & cancer. Feb 2004;42(2):169-175.
3. Poynter JN, Amatruda JF, Ross JA.
Trends in incidence and survival of pediatric and adolescent patients
with germ cell tumors in the United States, 1975 to 2006. Cancer.Oct 15 2010;116(20):4882-4891.
4. Einhorn LH, Donohue J.
Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination
chemotherapy in disseminated testicular cancer. Annals of internal
medicine. Sep 1977;87(3):293-298.
5. Marina NM, Cushing B, Giller R, et
al. Complete surgical excision is effective treatment for children with
immature teratomas with or without malignant elements: A Pediatric
Oncology Group/Children’s Cancer Group Intergroup Study. Journal
of clinical oncology : official journal of the American Society of
Clinical Oncology. Jul 1999;17(7):2137-2143.
6. Consolidated Report of Hospital
Based Cancer Registries 2012-2014. Bangalore: NCDIR-NCRP(ICMR);
2016:26-33.
7. Narula G, Prasad M, Jatia S, et al.
Clinicoepidemiological profiles, clinical practices, and the impact of
holistic care interventions on outcomes of pediatric hematolymphoid
malignancies - A 7-year audit of the pediatric hematolymphoid disease
management group at Tata Memorial Hospital. Indian journal of
cancer. Oct-Dec 2017;54(4):609-615.
8. Qureshi SS, Bhagat MG, Kembhavi SA,
et al. A cross-sectional study of the distribution of pediatric solid
tumors at an Indian tertiary cancer center. Indian journal of
cancer. Jan-Mar 2018;55(1):55-60.
9. Blohm ME, Vesterling-Horner D,
Calaminus G, Gobel U. Alpha 1-fetoprotein (AFP) reference values in
infants up to 2 years of age. Pediatric hematology and oncology.Mar-Apr 1998;15(2):135-142.
10. Olson TA, Murray MJ,
Rodriguez-Galindo C, et al. Pediatric and Adolescent Extracranial Germ
Cell Tumors: The Road to Collaboration. Journal of clinical
oncology : official journal of the American Society of Clinical
Oncology. Sep 20 2015;33(27):3018-3028.
11. Billmire DF, Cullen JW, Rescorla
FJ, et al. Surveillance after initial surgery for pediatric and
adolescent girls with stage I ovarian germ cell tumors: report from the
Children’s Oncology Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology. Feb 10
2014;32(5):465-470.
12. Shaikh F, Murray MJ, Amatruda JF,
et al. Paediatric extracranial germ-cell tumours. The Lancet.
Oncology. Apr 2016;17(4):e149-e162.
13. Rogers PC, Olson TA, Cullen JW,
et al. Treatment of children and adolescents with stage II testicular
and stages I and II ovarian malignant germ cell tumors: A Pediatric
Intergroup Study–Pediatric Oncology Group 9048 and Children’s Cancer
Group 8891. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology. Sep 1 2004;22(17):3563-3569.
14. Arora RS, Alston RD, Eden TO,
Geraci M, Birch JM. Comparative incidence patterns and trends of gonadal
and extragonadal germ cell tumors in England, 1979 to 2003.Cancer. Sep 1 2012;118(17):4290-4297.
15. Cushing B, Giller R, Cullen JW,
et al. Randomized comparison of combination chemotherapy with etoposide,
bleomycin, and either high-dose or standard-dose cisplatin in children
and adolescents with high-risk malignant germ cell tumors: a pediatric
intergroup study–Pediatric Oncology Group 9049 and Children’s Cancer
Group 8882. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology. Jul 1 2004;22(13):2691-2700.
16. Marina N, London WB, Frazier AL,
et al. Prognostic factors in children with extragonadal malignant germ
cell tumors: a pediatric intergroup study. Journal of clinical
oncology : official journal of the American Society of Clinical
Oncology. Jun 01 2006;24(16):2544-2548.
17. Palenzuela G, Martin E, Meunier
A, et al. Comprehensive staging allows for excellent outcome in patients
with localized malignant germ cell tumor of the ovary. Annals of
surgery. Nov 2008;248(5):836-841.
18. Saju SV, Radhakrishnan V, Ganesan
TS, et al. Factors that impact the outcomes in testicular germ cell
tumors in low-middle-income countries. Medical oncology. Feb 6
2019;36(3):28.
19. Flamant F, Baranzelli MC, Kalifa
C, Lemerle J. Treatment of malignant germ cell tumors in children:
experience of the Institut Gustave Roussy and the French Society of
Pediatric Oncology. Critical reviews in oncology/hematology.1990;10(2):99-110.
20. Haas RJ, Schmidt P, Gobel U,
Harms D. Testicular germ cell tumors, an update. Results of the German
cooperative studies 1982-1997. Klinische Padiatrie. Jul-Aug
1999;211(4):300-304.
21. Mann JR, Raafat F, Robinson K, et
al. The United Kingdom Children’s Cancer Study Group’s second germ cell
tumor study: carboplatin, etoposide, and bleomycin are effective
treatment for children with malignant extracranial germ cell tumors,
with acceptable toxicity. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology. Nov 15
2000;18(22):3809-3818.
22. Baranzelli MC, Kramar A, Bouffet
E, et al. Prognostic factors in children with localized malignant
nonseminomatous germ cell tumors. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology. Apr
1999;17(4):1212.
23. Gobel U, Schneider DT, Calaminus
G, et al. Multimodal treatment of malignant sacrococcygeal germ cell
tumors: a prospective analysis of 66 patients of the German cooperative
protocols MAKEI 83/86 and 89. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology. Apr 1
2001;19(7):1943-1950.
24. Murphy-Alford AJ, Prasad M, Slone
J, Stein K, Mosby TT. Perspective: Creating the Evidence Base for
Nutritional Support in Childhood Cancer in Low- and Middle-Income
Countries: Priorities for Body Composition Research. Advances in
Nutrition. 2019;11(2):216-223.
25. Thacker N, Pereira N, Banavali
SD, et al. Alarming prevalence of community-acquired multidrug-resistant
organisms colonization in children with cancer and implications for
therapy: A prospective study. Indian journal of cancer. Oct-Dec
2014;51(4):442-446.
26. Grimison PS, Stockler MR,
Chatfield M, et al. Accelerated BEP for metastatic germ cell tumours: a
multicenter phase II trial by the Australian and New Zealand Urogenital
and Prostate Cancer Trials Group (ANZUP). Annals of oncology :
official journal of the European Society for Medical Oncology. Jan
2014;25(1):143-148.
27. Mann JR, Pearson D, Barrett A,
Raafat F, Barnes JM, Wallendszus KR. Results of the United Kingdom
Children’s Cancer Study Group’s malignant germ cell tumor studies.Cancer. May 01 1989;63(9):1657-1667.
28. Schneider DT, Schuster AE,
Fritsch MK, et al. Genetic analysis of childhood germ cell tumors with
comparative genomic hybridization. Klinische Padiatrie. Jul-Aug
2001;213(4):204-211.
29. Frazier AL, Hale JP,
Rodriguez-Galindo C, et al. Revised risk classification for pediatric
extracranial germ cell tumors based on 25 years of clinical trial data
from the United Kingdom and United States. Journal of clinical
oncology : official journal of the American Society of Clinical
Oncology. Jan 10 2015;33(2):195-201.
30. Aass N, Klepp O, Cavallin-Stahl
E, et al. Prognostic factors in unselected patients with nonseminomatous
metastatic testicular cancer: a multicenter experience. Journal of
clinical oncology : official journal of the American Society of Clinical
Oncology. May 1991;9(5):818-826.
31. Frazier AL, Stoneham S,
Rodriguez-Galindo C, et al. Comparison of carboplatin versus cisplatin
in the treatment of paediatric extracranial malignant germ cell tumours:
A report of the Malignant Germ Cell International Consortium.European journal of cancer. Jul 2018;98:30-37.
32. Kapoor G, Advani SH, Nair CN, et
al. Pediatric germ cell tumor. An experience with BEP. Journal of
pediatric hematology/oncology. Nov 1995;17(4):318-324.